Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma

Authors :: Andres Forero-Torres
M. Pashkevich
Damien M. Cronier
Noopur Raje
Paul G. Richardson
James E. Wooldridge
KC Anderson
Gary J. Schiller
Edward A. Faber
Raymond J. Hohl
Susan P. Carpenter
Adam D. Cohen
Source :: Journal of Clinical Oncology. 29:8012-8012
Publication Year :: 2011
Publisher :: American Society of Clinical Oncology (ASCO), 2011.
Abstract: 8012 Background: LY2127399 (LY) is a human mAb that neutralizes membrane-bound and soluble B cell activating factor (BAFF). LY has activity in xenograft models of multiple myeloma (MM) and is being...

Full Text Access

Tools